Rearrangements and Amplification of IER3 (IEX-1) Represent a Novel and Recurrent Molecular Abnormality in Myelodysplastic Syndromes
Open Access
- 1 October 2009
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (19) , 7518-7523
Abstract
IER3 (formerly IEX-1) encodes a 27-kDa glycoprotein that regulates death receptor–induced apoptosis, interacts with NF-κB pathways, and increases expression rapidly in response to cellular stresses such as irradiation. Animal models, gene expression microarray experiments, and functional studies in cell lines have suggested a potential role for IER3 in oncogenesis, but, to date, no abnormalities of IER3 at the DNA level have been reported in patients with neoplasia. Here, we describe breakpoint cloning of a t(6;9)(p21;q34) translocation from a patient with a myelodysplastic syndrome (MDS), facilitated by conversion technology and array-based comparative genomic hybridization, which revealed a rearrangement translocating the IER3 coding region away from critical flanking/regulatory elements and to a transcript-poor chromosomal region, markedly decreasing expression. Using split-signal and locus-specific fluorescence in situ hybridization (FISH) probes, we analyzed 204 patients with diverse hematological malignancies accompanied by clonal chromosome 6p21 abnormalities, and found 8 additional patients with MDS with IER3 rearrangements (translocations or amplification). Although FISH studies on 157 additional samples from patients with MDS and a normal-karyotype were unrevealing, and sequencing the IER3 coding and proximal promoter regions of 74 MDS patients disclosed no point mutations, reverse transcription-PCR results suggested that dysregulated expression of IER3 is common in MDS (61% >4-fold increase or decrease in expression with decreased expression primarily in early MDS and increased expression primarily in later MDS progressing toward leukemia), consistent with findings in previous microarray experiments. These data support involvement of IER3 in the pathobiology of MDS. [Cancer Res 2009;69(19):7518–23]Keywords
All Related Versions
This publication has 20 references indexed in Scilit:
- Differential gene expression of bone marrow-derived CD34+ cells is associated with survival of patients suffering from myelodysplastic syndromeInternational Journal of Hematology, 2009
- Prognostic Significance of the Immediate Early Response Gene X-1 (IEX-1) Expression in Pancreatic CancerAnnals of Surgical Oncology, 2007
- Conversion Technology for the Separation of Maternal and Paternal Copies of Any Autosomal Chromosome in Somatic Cell HybridsCurrent Protocols in Human Genetics, 2007
- The apoptosis-inducing effect of gastrin on colorectal cancer cells relates to an increased IEX-1 expression mediating NF-κB inhibitionOncogene, 2007
- Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylationBlood, 2006
- Elevated blood pressure and cardiac hypertrophy after ablation of thegly96/IEX-1geneJournal of Applied Physiology, 2006
- Immediate early gene X-1 (IEX-1), a hydroxytamoxifen regulated gene with increased stimulation in MCF-7 derived resistant breast cancer cellsThe Journal of Steroid Biochemistry and Molecular Biology, 2004
- Development of T-cell lymphomas in Eμ-IEX-1 miceOncogene, 2003
- Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrowBlood, 2002
- IEX -1L, an Apoptosis Inhibitor Involved in NF-κB-Mediated Cell SurvivalScience, 1998